Oppenheimer Issues Mid-Day Note on MEI Pharma: ME-401 'could be a highly competitive PI3K inhibitor with a preferred safety profile,' Highlights There Have Been No Reports of ALT/AST Elevations, Colitis or Pneumonitis
Paul Quintaro